NCT00508404View on ClinicalTrials.gov

Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 9, 2007

Primary Completion Date

June 1, 2009

Study Completion Date

June 12, 2012

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Panitumumab

Administered by intravenous infusion

DRUG

FOLFIRI

FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY